Heartflow Q1 Earnings Call Highlights
Heartflow NASDAQ: HTFL reported a sharply higher first-quarter revenue total and raised its full-year 2026 outlook, citing strength in its core FFRCT business, faster-than-expected adoption of its Plaque Analysis product and continued expansion of the coronary CT angiography, or CCTA, market.
HeartFlow, Inc. (HTFL) Q1 2026 Earnings Call Transcript
HeartFlow, Inc. (HTFL) Q1 2026 Earnings Call Transcript
HeartFlow: Getting Into The Flow
HeartFlow delivered 40% sales growth in 2025, with revenue surpassing $176 million and strong Q4 momentum. 2026 guidance targets 25% revenue growth to $218–222 million, with gross margins rising to 80–81% and further mid-term upside to 85%. HearthFlow's AI-driven CAD diagnostic platform is gaining adoption, supported by FDA-cleared next-generation algorithms and a proprietary CT image database.
HeartFlow, Inc. (HTFL) Q4 2025 Earnings Call Transcript
HeartFlow, Inc. (HTFL) Q4 2025 Earnings Call Transcript
Bamco Inc. NY Takes $41.65 Million Position in Heartflow, Inc. $HTFL
Bamco Inc. NY purchased a new stake in shares of Heartflow, Inc. (NASDAQ: HTFL) during the undefined quarter, according to its most recent disclosure with the SEC. The fund purchased 1,237,506 shares of the company's stock, valued at approximately $41,654,000. Bamco Inc. NY owned about 1.45% of Heartflow at the end of the
Capital International Investors Invests $43.67 Million in Heartflow, Inc. $HTFL
Capital International Investors purchased a new stake in shares of Heartflow, Inc. (NASDAQ: HTFL) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,297,423 shares of the company's stock, valued at approximately $43,671,000. Capital International Investors owned 1.56% of Heartflow
